MCM
PCVX icon

Moore Capital Management’s Vaxcyte PCVX Stock Holding History

Moore Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-172,500
Closed -$8.27M – 562
2022
Q4 		$8.27M Buy
172,500
+28,534
+20% +$1.12M 0.2% 99
2022
Q3 		$3.46M Buy
143,966
+63,665
+79% +$1.61M 0.08% 263
2022
Q2 		$1.75M Buy
+80,301
New +$1.86M 0.05% 354

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Moore Capital Management's PCVX Position: Q1 2023 in Review

Moore Capital Management sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 172,500 shares — an estimated $8.27M sold.

Moore Capital Management first reported a position in PCVX in Q2 2022 and held it in 3 quarters. The position peaked at $8.27M in Q4 2022. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

  • Moore Capital Management reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
  • Moore Capital Management sold 172,500 Vaxcyte shares in Q1 2023, an estimated $8.27M.
  • Moore Capital Management first reported a position in Vaxcyte in Q2 2022 and held it in 3 quarters.
  • Moore Capital Management's Vaxcyte position peaked at $8.27M in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.